KYTX
Kyverna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.85
−0.68%Oct 21, 2026, 11:15 UTC
Kyverna Therapeutics, Inc. presented one-year registrational data for miv-cel in stiff person syndrome, reporting sustained clinical benefit across all primary and secondary endpoints and that nearly all patients remained off chronic immunotherapies.
Source:Sep 24, 2026, 10:00 UTC
Kyverna Therapeutics reported positive one-year data showing durable clinical responses and a favorable safety profile for miv-cel in stiff person syndrome and generalized myasthenia gravis.
Source:Aug 11, 2026, 20:02 UTC
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutics' miv-cel for the treatment of non-active secondary progressive multiple sclerosis (naSPMS).
Source:Jul 27, 2026, 12:00 UTC
Kyverna Therapeutics and ElevateBio entered into a commercial manufacturing and supply agreement for Miv-cel.
Source:Jul 27, 2026, 00:00 UTC
Kyverna Therapeutics signed a Clinical and Commercial Supply Agreement with ElevateBio Basecamp for development and manufacturing services for its lead product candidate mivocabtagene autoleucel (miv-cel).
Jul 9, 2026, 00:00 UTC
Kyverna Therapeutics entered into a Loan and Security Agreement with Oxford Finance LLC for a term loan facility of up to $150.0 million, with $25.0 million drawn in November 2025.